In today’s briefing:
- Neuren Pharmaceuticals (NEU AU): Daybue US Sales and Geography Expansion to Drive Growth
- QNRX: More Positive Data Supporting Efficacy of QRX003 for NS Campaign to Raise Awareness of the Disease
Neuren Pharmaceuticals (NEU AU): Daybue US Sales and Geography Expansion to Drive Growth
- Neuren Pharmaceuticals (NEU AU) received A$56M U.S. royalty income from Daybue in 2024 up 110% from A$27M in 2023. Cumulative income from Daybue reached to A$445M over 2023 and 2024.
- Assuming Daybue U.S. sales guidance is met and an exchange rate of 0.65, Neuren anticipates earning U.S. royalties of A$62–67M, up 15% YoY at mid-point in 2025.
- Daybue will be launched in Canada in 3Q25. European approval is expected in 1Q26. For Japan, Acadia plans to initiate small clinical study by 3Q25 to support a marketing application.
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS Campaign to Raise Awareness of the Disease
- There are no approved NS treatments currently & Quoin is optimistic that QRX003 can become the first.
- The overall patient population is fairly sizable QNRX estimates there are ~6k-7k patients in the U.S. and EU.
- Moreover, NS is often undiagnosed.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
